NIH
"A randomized clinical trial of estrogen therapy in younger
postmenopausal women, aged 50–55, has found no long-term risk or
benefit to cognitive function. The National Institutes of
Health-supported study, reported in JAMA Internal Medicine on June 24,
2013, looked at women taking conjugated equine estrogens, the most
common type of postmenopausal hormone therapy in the United States.
The earlier Women’s Health Initiative Memory Study
(WHIMS) linked the same type of hormone therapy to cognitive decline
and dementia in older postmenopausal women...........
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.